MOTS-c and Rivaroxaban Interaction: Safety, Mechanism, and Monitoring
Clinical analysis of the MOTS-c mitochondrial peptide and rivaroxaban (Xarelto) drug interaction, covering CYP3A4/P-gp pharmacokinetics, bleeding risk, and monitoring recommendations.